Indivior Pharmaceuticals, Inc. INDV Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $175M-10.3% | $195M-56.2% | $445M-12.7% | $510M+37.1% | $372M+16.6% | ||
| $273M+7.9% | $253M-2.3% | $259M+7.9% | $240M-1.2% | $243M-4.3% | ||
| $1M-50.0% | $2M+100% | $1M-94.1% | $17M+41.7% | $12M+20.0% | ||
| $667M+2.3% | $652M-29.3% | $922M-3.0% | $951M+7.7% | $883M+6.8% | ||
| $157M+9.0% | $144M+16.1% | $124M+6.0% | $117M+12.5% | $104M+4.0% | ||
| $2M0.0% | $2M0.0% | $2M-71.4% | $7M0.0% | $7M+16.7% | ||
| $1.2B-0.3% | $1.2B-15.2% | $1.42B-2.5% | $1.45B+5.6% | $1.38B+4.5% | ||
| $35M-27.1% | $48M+17.1% | $41M-18.0% | $50M+8.7% | $46M-27.0% | ||
| $0-100% | $29M+61.1% | $18M0.0% | $18M0.0% | $18M0.0% | ||
| $779M-14.8% | $914M-5.3% | $965M-8.6% | $1.06B+5.1% | $1.01B+8.8% | ||
| $486M+67.6% | $290M-4.6% | $304M-1.3% | $308M-1.0% | $311M-1.3% | ||
| $1.34B+3.2% | $1.3B-19.9% | $1.62B-5.0% | $1.71B+3.0% | $1.66B+0.5% | ||
| $0-100% | $62M0.0% | $62M0.0% | $62M0.0% | $62M0.0% | ||
| -$280M-15.2% | -$243M+29.8% | -$346M+10.8% | -$388M+4.4% | -$406M+8.4% | ||
| -$144M-46.9% | -$98M+52.7% | -$207M+19.5% | -$257M+9.8% | -$285M+15.4% | ||
| $1.2B-0.3% | $1.2B-15.2% | $1.42B-2.5% | $1.45B+5.6% | $1.38B+4.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Indivior Pharmaceuticals, Inc. cover its short-term obligations?
- Its current ratio is 0.86 — current liabilities exceed current assets.
- Where does Indivior Pharmaceuticals, Inc. 's balance sheet data come from?
- Every line is extracted from Indivior Pharmaceuticals, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.